PURPOSE: A [11C]UCB-J blocking study was performed in healthy volunteers to validate simplified, non-invasive measures for quantifying presynaptic SV2A expression using subcortical white matter as reference tissue. METHODS: Ninety minutes dynamic [11C]UCB-J PET scanning with arterial blood sampling was performed in 10 healthy volunteers (8 M/2F; age 27.6 ± 10.0 yrs), before and after administration of a novel chemical entity with selective affinity for SV2A. The centrum semi-ovale (SO) was validated as reference region by comparing baseline and post treatment distribution volume (VT). Using SO as reference tissue, Binding Potential (BPSO) using a Simplified Reference Tissue Model (SRTM, down to 60 min acquisition) and Standardized Uptake Value Ratios (60-90 min post injection - SUVRSO,60-90min) were compared with regional distribution volume ratios (DVR). Next, SV2A occupancy values based on SRTM BPSO and SUVRSO,60-90min were compared to occupancy estimates using regional VT values and a Lassen plot. RESULTS: After pretreatment, regional VT values were reduced significantly except for SO. Highly significant correlations were found between DVR, SRTM BPSO and SUVRSO,60-90min. Compared to DVR, baseline SRTM BPSO showed a small bias (≤ 6.1%) with lower precision for shorter acquisition times, while SUVRSO,60-90min showed 3.5% bias with similar precision. Differences between SV2A occupancy values based on SUVRSO,60-90min and occupancy estimates using VT and a Lassen plot were small but significant, while negligible bias was found for SRTM based occupancy estimates (at least 70 min acquisition). CONCLUSION: This [11C]UCB-J blocking study validated SO as a suitable reference region for non-invasive quantification of SV2A availability and drug occupancy in the human brain. Accurate quantification can be achieved by using either SUVRSO,60-90min with a 60-90 min PET acquisition or SRTM BPSOwith at least 70 min dynamic PET acquisition.
PURPOSE: A [11C]UCB-J blocking study was performed in healthy volunteers to validate simplified, non-invasive measures for quantifying presynaptic SV2A expression using subcortical white matter as reference tissue. METHODS: Ninety minutes dynamic [11C]UCB-J PET scanning with arterial blood sampling was performed in 10 healthy volunteers (8 M/2F; age 27.6 ± 10.0 yrs), before and after administration of a novel chemical entity with selective affinity for SV2A. The centrum semi-ovale (SO) was validated as reference region by comparing baseline and post treatment distribution volume (VT). Using SO as reference tissue, Binding Potential (BPSO) using a Simplified Reference Tissue Model (SRTM, down to 60 min acquisition) and Standardized Uptake Value Ratios (60-90 min post injection - SUVRSO,60-90min) were compared with regional distribution volume ratios (DVR). Next, SV2A occupancy values based on SRTM BPSO and SUVRSO,60-90min were compared to occupancy estimates using regional VT values and a Lassen plot. RESULTS: After pretreatment, regional VT values were reduced significantly except for SO. Highly significant correlations were found between DVR, SRTM BPSO and SUVRSO,60-90min. Compared to DVR, baseline SRTM BPSO showed a small bias (≤ 6.1%) with lower precision for shorter acquisition times, while SUVRSO,60-90min showed 3.5% bias with similar precision. Differences between SV2A occupancy values based on SUVRSO,60-90min and occupancy estimates using VT and a Lassen plot were small but significant, while negligible bias was found for SRTM based occupancy estimates (at least 70 min acquisition). CONCLUSION: This [11C]UCB-J blocking study validated SO as a suitable reference region for non-invasive quantification of SV2A availability and drug occupancy in the human brain. Accurate quantification can be achieved by using either SUVRSO,60-90min with a 60-90 min PET acquisition or SRTM BPSOwith at least 70 min dynamic PET acquisition.
Authors: Guomei Tang; Kathryn Gudsnuk; Sheng-Han Kuo; Marisa L Cotrina; Gorazd Rosoklija; Alexander Sosunov; Mark S Sonders; Ellen Kanter; Candace Castagna; Ai Yamamoto; Zhenyu Yue; Ottavio Arancio; Bradley S Peterson; Frances Champagne; Andrew J Dwork; James Goldman; David Sulzer Journal: Neuron Date: 2014-08-21 Impact factor: 17.173
Authors: Vincent J Cunningham; Eugenii A Rabiner; Mark Slifstein; Marc Laruelle; Roger N Gunn Journal: J Cereb Blood Flow Metab Date: 2009-09-09 Impact factor: 6.200
Authors: Koon-Pong Wong; Mirwais Wardak; Weber Shao; Magnus Dahlbom; Vladimir Kepe; Jie Liu; Nagichettiar Satyamurthy; Gary W Small; Jorge R Barrio; Sung-Cheng Huang Journal: Eur J Nucl Med Mol Imaging Date: 2009-10-31 Impact factor: 9.236
Authors: Sandeep S V Golla; Sofie M Adriaanse; Maqsood Yaqub; Albert D Windhorst; Adriaan A Lammertsma; Bart N M van Berckel; Ronald Boellaard Journal: EJNMMI Phys Date: 2017-12-06
Authors: Isadora Lopes Alves; David Vállez García; Andrea Parente; Janine Doorduin; Rudi Dierckx; Ana Maria Marques da Silva; Michel Koole; Antoon Willemsen; Ronald Boellaard Journal: EJNMMI Res Date: 2017-02-22 Impact factor: 3.138
Authors: Nathalie Mertens; Ralph Paul Maguire; Kim Serdons; Brigitte Lacroix; Joel Mercier; David Sciberras; Koen Van Laere; Michel Koole Journal: Mol Imaging Biol Date: 2020-04 Impact factor: 3.488
Authors: Samantha Rossano; Takuya Toyonaga; Sjoerd J Finnema; Mika Naganawa; Yihuan Lu; Nabeel Nabulsi; Jim Ropchan; Steven De Bruyn; Christian Otoul; Armel Stockis; Jean-Marie Nicolas; Paul Martin; Joel Mercier; Yiyun Huang; R Paul Maguire; Richard E Carson Journal: J Cereb Blood Flow Metab Date: 2019-09-30 Impact factor: 6.200
Authors: Greet Vanderlinden; Jenny Ceccarini; Thomas Vande Casteele; Laura Michiels; Robin Lemmens; Eric Triau; Kim Serdons; Jos Tournoy; Michel Koole; Mathieu Vandenbulcke; Koen Van Laere Journal: Mol Psychiatry Date: 2022-07-06 Impact factor: 15.992
Authors: Andrea I Luppi; Pedro A M Mediano; Fernando E Rosas; Negin Holland; Tim D Fryer; John T O'Brien; James B Rowe; David K Menon; Daniel Bor; Emmanuel A Stamatakis Journal: Nat Neurosci Date: 2022-05-26 Impact factor: 28.771
Authors: Javad Khodaii; Mostafa Araj-Khodaei; Manouchehr S Vafaee; Dean F Wong; Albert Gjedde Journal: J Nucl Med Date: 2021-06-04 Impact factor: 10.057
Authors: June van Aalst; Jenny Ceccarini; Stefan Sunaert; Patrick Dupont; Michel Koole; Koen Van Laere Journal: J Cereb Blood Flow Metab Date: 2021-01-14 Impact factor: 6.200
Authors: Hayel Tuncel; Ronald Boellaard; Emma M Coomans; Erik Fj de Vries; Andor Wjm Glaudemans; Paula Kopschina Feltes; David V García; Sander Cj Verfaillie; Emma E Wolters; Steven P Sweeney; J Michael Ryan; Magnus Ivarsson; Berkley A Lynch; Patrick Schober; Philip Scheltens; Robert C Schuit; Albert D Windhorst; Peter P De Deyn; Bart Nm van Berckel; Sandeep Sv Golla Journal: J Cereb Blood Flow Metab Date: 2020-10-08 Impact factor: 6.200
Authors: Elijah Mak; Negin Holland; P Simon Jones; George Savulich; Audrey Low; Maura Malpetti; Sanne S Kaalund; Luca Passamonti; Timothy Rittman; Rafael Romero-Garcia; Roido Manavaki; Guy B Williams; Young T Hong; Tim D Fryer; Franklin I Aigbirhio; John T O'Brien; James B Rowe Journal: Neurobiol Aging Date: 2021-01-30 Impact factor: 4.673